Aruna Kamineni, PhD, MPH

“I'm working on reducing cancer through better screening. I collaborate with researchers nationwide on studies that will make screening more effective, patient-friendly, and personalized.”

Aruna Kamineni, PhD, MPH

Assistant Investigator, Kaiser Permanente Washington Health Research Institute

Aruna.S.Kamineni@kp.org
206-287-2922

Curriculum vitae (CV)

Biography

Aruna Kamineni, PhD, MPH, came to Kaiser Permanente Washington Health Research Institute in 2009 with a wealth of experience in chronic disease epidemiology. Dr. Kamineni has expertise in using case-control methods to evaluate screening efficacy, and her research focuses on addressing evidence gaps for clinical guidelines, particularly for cervical and colorectal cancer prevention. A substantial portion of her work has focused on developing infrastructure and methods for research using electronic clinical and administrative health care data.

Since 2011, Dr. Kamineni has participated in the National Cancer Institute’s Population-based Research to Optimize the Screening Process (PROSPR) consortium to evaluate and improve cancer screening in U.S. community settings. As a principal investigator for multisite cervical and colorectal cancer PROSPR Research Centers, Dr. Kamineni is leading and collaborating on work to determine how to optimally use screening tests and consider how to tailor screening for population subgroups.

Dr. Kamineni’s research goals include studying the impact of human papillomavirus (HPV) DNA testing and HPV vaccination on cervical cancer and screening programs. Multidisciplinary collaboration is a valued and important driver of Dr. Kamineni’s research and she embraces a team science approach to optimizing cancer prevention.

Research interests and experience

Cancer

Cervical cancer; colorectal cancer; screening; disparities
Methods

Electronic clinical and administrative data infrastructure development for research; case-control studies; team science

Recent publications

Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. 2018 May;113(5):746-754. doi: 10.1038/s41395-018-0023-x. Epub 2018 Feb 27. PubMed

Balasubramanian BA, Garcia MP, Corley DA, Doubeni CA, Haas JS, Kamineni A, Quinn VP, Wernli K, Zheng Y, Skinner CS. Racial/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems. Medicine (Baltimore). 2017;96(11):e6326. doi: 10.1097/MD.0000000000006326. PubMed

Habbema D, Weinmann S, Arbyn M, Kamineni A, Williams AE, M C M de Kok I, van Kemenade F, Field TS, van Rosmalen J, Brown ML. Harms of cervical cancer screening in the United States and the Netherlands. Int J Cancer. 2017 Mar 1;140(5):1215-1222. doi: 10.1002/ijc.30524. PubMed

Shortreed SM, Johnson EJ, Rutter CM, Kamineni A, Wernli KJ, Chubak J. Cohort restriction based on prior enrollment: Examining potential biases in estimating cancer and mortality risk. Obs Stud. 2016 Aug;2:51-64. Epub 2016 Sep 26. PubMed

Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget. 2016 Oct 11;7(41):66328-66343. doi: 10.18632/oncotarget.11041. PubMed

Hubbard R, Johnson E, Chubak J, Wernli KJ, Kamineni A, Bogart A, Rutter C. Estimating screening test effectiveness when screening indication is unknown using generalized linear finite mixture models. Health Services Outcomes Res Methodol.2017 17(2):101-112.

Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, Kamineni R, Schapira MM, Vacek PM, Garcia MP, Corley DA on behalf of PROSPR consortium. Influence of age and comorbidity on colorectal cancer screening in the elderly. Am J Prev Med. 2016 Sep;51(3):e67-75. doi: 10.1016/j.amepre.2016.04.018. Epub 2016 Jun 22. PubMed

Hubbard RA, Johnson E, Chubak J, Wernli K, Kamineni A, Bogart A, Rutter CM. Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. Health Serv Outcomes Res Methodol. 2017 Jun;17(2):101-112. doi: 10.1007/s10742-016-0149-5. Epub 2016 Jun 3. PubMed

Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Apr 12. doi: 10.7326/M15-2117. [Epub ahead of print]. PubMed

Chubak J, Garcia MP, Burnett-Hartman AN, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM; PROSPR consortium. Time to colonoscopy after positive fecal blood test in four US healthcare systems. Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):344-50. doi: 10.1158/1055-9965.EPI-15-0470.Cancer Epidemiol Biomarkers Prev. 2016 Feb 3. [Epub ahead of print]. PubMed